Loading
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
Previous close
$5.28
+$0.19 · +3.73%
Regular session · ET · Market data may be delayed.
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
Day range
Current $5.28
52-week range
Current $5.28
Regular session · ET · Market data may be delayed.
GoAI Score
Strong sell
Valuation
2
Overpriced
Sentiment
51
Mixed
Risk
70
High Risk
Momentum
22
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
Day range
Current $5.28
52-week range
Current $5.28
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 71K USD | 3M USD | 2.45M USD | 377K USD | 500K USD |
| Cost of goods sold | 323K USD | 6.04M USD | 6.42M USD | 3.61M USD | 585K USD |
| Gross profit | −252K USD | −3.04M USD | −3.97M USD | −3.24M USD | −85K USD |
| Research and development | 4.49B USD | 5.93M USD | 14.28M USD | 25.34M USD | 19.85M USD |
| Selling, general, and administrative | 17.17B USD | 36.15M USD | 48.53M USD | 60.73M USD | 34.32M USD |
| Operating expenses | 21.55M USD | 41.44M USD | 64.83M USD | 87.85M USD | 54.31M USD |
| Interest income | 29K USD | 254K USD | 505K USD | 169K USD | — |
| Interest expense | 21K USD | 45K USD | 589K USD | 1.28M USD | — |
| Depreciation and amortization | 105K USD | 1.2M USD | 2.93M USD | 2.46M USD | 226K USD |
| Operating income | −21.81M USD | −44.49M USD | −68.8M USD | −91.09M USD | −54.39M USD |
| Net income | 401K USD | 39.79M USD | −64.18M USD | −88.98M USD | −50.35M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 2, 2026 | 1:30 | — | — |
Stock split | Dec 7, 2023 | 1:15 | — | — |
Effective Jan 2, 2026
1:30
Effective Dec 7, 2023
1:15
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
